Allergan Gets Competing Merger Offer To Ackman’s Pershing Square, Valeant

Allergan, Inc. (NYSE:AGN) has been in the news often throughout the year so far.  Beginning on April 22, 2014, Valeant Pharmaceuticals Intl Inc (NYSEVRX) (TSE:VRX) approached the board of Allergan with the interest of acquiring the botox maker, which was valued around $152.88 per share.  Early May 2014, Allergan decided against the proposal and voted against the acquisition.  Only a few weeks later, around May 28th, Pershing Square Capital manager, Bill Ackman, got onboard and eyed a joint acquisition with Valeant of Allergan.  However, as several months went by, no new progress was being made by Ackman and Valeant.  In…